Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C36H40ClN9O5S
CAS Number:
Molecular Weight:
746.28
UNSPSC Code:
12352200
NACRES:
NA.21
InChI key
AJNQGWOQPRWRML-UHFFFAOYSA-N
SMILES string
CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCCNC(COC5=CC=C(C=C5)C6CCC(NC6=O)=O)=O)=N1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Potent ABL and SRC family tyrosine kinases (TYKs) degrader with greater antileukemic efficacy than dasatinib in cultures and in vivo.
SJ11646 is a potent and high-affinity (LCK/ABL1/SRC Kd = 0.14/0.054/0.17 nM for SJ11646 vs. 0.09/0.054/0.19 nM for dasatinib) ABL and SRC family tyrosine kinases (TYKs) degrader composed of dasatinib linked to a E3 ligase cereblon (CRBN)-binding ligand. SJ11646 effectively degrades SRC family TYKs in KOPT-K1 cells (LCK, CSK, SRC, FYN; 100 nM for 24h) and is 55,114-times more cytotoxic (LC50 = 0.0123 pM) than dasatinib against the BCR-ABL fusion-harboring B-ALL cell line SUP-B15. When used at equal molar amount via daily i.p., SJ11646 (15 mg/kg) shows significantly greater antileukemic efficacy than dasatinib (10 mg/kg) in two T-ALL PDX models in mice in vivo.
SJ11646 is a potent and high-affinity (LCK/ABL1/SRC Kd = 0.14/0.054/0.17 nM for SJ11646 vs. 0.09/0.054/0.19 nM for dasatinib) ABL and SRC family tyrosine kinases (TYKs) degrader composed of dasatinib linked to a E3 ligase cereblon (CRBN)-binding ligand. SJ11646 effectively degrades SRC family TYKs in KOPT-K1 cells (LCK, CSK, SRC, FYN; 100 nM for 24h) and is 55,114-times more cytotoxic (LC50 = 0.0123 pM) than dasatinib against the BCR-ABL fusion-harboring B-ALL cell line SUP-B15. When used at equal molar amount via daily i.p., SJ11646 (15 mg/kg) shows significantly greater antileukemic efficacy than dasatinib (10 mg/kg) in two T-ALL PDX models in mice in vivo.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jianzhong Hu et al.
Science translational medicine, 14(659), eabo5228-eabo5228 (2022-08-25)
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, and there is an unmet need for targeted therapies, especially for patients with relapsed disease. We have recently identified pre-T cell receptor and lymphocyte-specific protein tyrosine kinase (LCK) signaling
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service